Drug Resistance as a Biochemical Target in Cancer Chemotherapy
The development of drug resistance hinders the effectiveness of cancer chemotherapy. While it is a complex problem, some remarkable findings have emerged from recent molecular biological and biochemical studies that are helping to shed light on the molecular mechanisms of drug resistance. Based on these findings, new therapeutic approaches targeting drug resistance mechanisms are being tested. This volume summarizes results of the latest preclinical and clinical studies on the circumvention of drug resistance.
- Hardback | 342 pages
- 165.1 x 230 x 19.05mm | 681g
- 01 Jan 1992
- Elsevier Science Publishing Co Inc
- Academic Press Inc
- San Diego, United States
Table of contents
Part 1 Genetic aspects of multidrug resistance: introduction to the Bristol-Myers Squibb drug resistance in cancer symposium, G.A. Curt; the P-Glycoprotein gene family, P. Borst, et al; molecular genetic analysis of P-Glycoprotein function and expression in human cells, I.B. Roninson, et al; function of the multidrug transporter, M.G. Gottesman, et al; a comparison of the structure, function, and expression of P-Glycoproteins encoded by mdrla and mdrlb in mouse, L.M. Greenberger, et al. Part 2 Proteins involved in drug resistance as targets for cancer chemotherapy: multidrug resistance - basic approaches for reversal, T. Tsuruo; expression of P-Glycoprotein isoforms in normal and malignant cells, V. Ling; the use of yeast and yeast strains expressing human DNA topoisomerase in the study of anticancer drugs, P. Benedetti, et al; mechanisms of tumour cell killing by toposomerase poisons, P. D'Arpa, et al; regulation of glutathione transferase P gene implicatons in carcinogenesis and drug resistance, M. Muramatsu, et al. Part 3 Basic approaches against clinical drug resistance: clinical detection and role of differentiation in multidrug resistance, T. Fojo, et al; detection of multidrug resistant human cancer cells by monoclonal antibodies, M. Shimoyama; molecular analysis of human IL-2 and IL-2 receptors, T. Taniguchi, et al; the interactions among steroid hormones, steroid hormone receptors, antiestrogens, biological response modifiers, and cytotoxic drugs, R. Clarke and R.B. Dickson. Part 4 Clinical approaches against drug failure: clinical detection of multidrug resistance and reversal with chemosensitizing agents, S.E. Salmon, et al; clinical evaluation of non-cross-resistant therapies in advanced Hodgkin's Disease, G. Bonadonna, et al; autologous bone marrow transplantation for haematologic malignancy, G.L. Phillips; dose intensive therapy - a strategy to avoid drug resistance in solid tumours, K. Antman; high dose chemotherapy with autologous bone marrow transplantation on malignant lymphomas and breast cancer.